布里斯托尔·迈尔斯·斯奎布(Bristol Myers Squibbb)击败了收入估算,提高了股息,并保持全年指导,尽管内幕销售。 Bristol Myers Squibb beat earnings estimates, raised dividend, and kept full-year guidance despite insider sales.

布里斯托尔·迈尔斯·斯基布报告说,第二季度收入为每股1.46美元,粗略估计,收入为122.7亿美元,比上一年增加0.6%。 Bristol Myers Squibb reported second-quarter earnings of $1.46 per share, beating estimates, with revenue of $12.27 billion, up 0.6% year-over-year. 该公司重申其2025年全年EPS准则,即6.35-6.65美元,并宣布季度股息为每股0.62美元,收益为5.6%。 The company reaffirmed its 2025 full-year EPS guidance at $6.35–$6.65 and declared a quarterly dividend of $0.62 per share, yielding 5.6%. 尽管高管进行了内幕出售，包括执行副总裁 David V. Elkins 以 792 万美元退出，但机构所有权仍然强劲。 Despite executive insider sales, including a $7.92 million exit by EVP David V. Elkins, institutional ownership remains strong. 分析师保持一致的“控股”评级,引用股票的深值潜力、稳定的红利以及肿瘤学和免疫学的稳健管道。 Analysts maintain a consensus "hold" rating, citing the stock’s deep value potential, stable dividend, and robust pipeline in oncology and immunology.